This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"

ANDO Portugal will be holding a Webinar with QED Therapeutics on 24 September at 6pm (UTC/GMT +1) as part of an innovative series focused on new treatments for skeletal dysplasias.

Details

 

Innovation & Therapeutics | ANDO Webinar with QED Therapeutics
Title: QED Clinical Development Program Update

Guest: Elena Muslimova MD, PhD and Medical Director for the ACCEL Hypochondroplasia Program.

Organiser: ANDO Portugal
Date: 24 September 2024 - 18:00 (UTC/GMT +1)
Webinar Language: English

Important Topics:
1. Presentation of the clinical programs under study, namely PROPEL (achondroplasia) and ACCEL (hypochondroplasia).
2. Q&A about the studies carried out and the results obtained.
3. The way forward: next steps in the studies.
4. Collaboration: understanding the importance of collaboration between pharmaceutical companies and other stakeholders (patients, families and organisations) in advancing healthcare.

Free Access and Participation:
Participation is open to those interested in skeletal dysplasia care and research. Participate: during the webinar, ask questions in the chat. Missed a webinar? Don't worry, it will be recorded, subtitled and shared on ANDO's website for everyone to access.

How to take part:
Taking part is easy. Simply register for free using the form and you'll receive instructions on how to join the live session. Don't miss this opportunity to keep up with innovation in skeletal dysplasias.

Register Here
To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.


Thank You.